conducted a phase II clinical trial using dendritic cell-derived exosomes carrying MHC-I and MHC-II and loaded with IFN-γ (IFN-γ-Dex) to treat non-small cell lung cancer (NSCLC) patients, confirming the ability of Dex to enhance NK cell anti-tumor immunity in advanced NSCLC patients (188). The gene discussed is IFNG; the disease is non-small cell lung carcinoma.